Omnipod 5 Android App Recalled Due to Insulin Overdose Risk

Nearly 30,000 Omnipod 5 insulin delivery systems are being recalled over the risk that the devices may delivery incorrect insulin doses.

Federal health officials have announced a class I recall of the Omnipod 5 Android App, which is designed to control certain insulin delivery systems, due to a risk that software errors may cause the devices to provide incorrect doses of insulin to users, increasing the risk of severe and potentially fatal injuries.

The U.S. Food & Drug Administration has issued the Omnipod 5 Android App recall on November 7, 2023, after discovering problems with the software may allow users to administer up to ten times the desired insulin dose from Insulet’s Omnipod 5 automated pump.

Officials are warning that an accidental over delivery of insulin could result in both mild and severe hypoglycemia. Symptoms of mild hypoglycemia include sweating, clamminess, chills, dizziness, confusion, anxiety, rapid heartbeat, hunger, irritability, blurred vision, and tingling of the mouth. Severe reactions to an increased insulin dosage could potentially result in a hypoglycemic coma, which, in extreme cases, may lead to death.

Omnipod 5 Android App Recall

The recall impacts the Omnipod 5 App that is used to control insulin dosages delivered through the Omnipod 5 system for individuals two years of age or older with type I diabetes. The app utilizes ‘SmartAdjust’ technology, which adjusts the insulin delivery based on current and future blood sugar levels.

Do You Know About...

Childhood Diabetes Lawsuits Against Junk Food Industry

Lawyers are now pursuing financial compensation for families of children diagnosed with Type II diabetes, fatty liver disease and other chronic illnesses caused by addictive and harmful substances in ultra-processed foods.

Learn More

Officials are warning that when the user enters a bolus amount less than 1 unit without including a leading zero before the decimal point, the app may fail to register the decimal point correctly. As a result, the app will send a command to deliver insulin at the level of the first character entered, rather than the intended amount.

If a user enters ‘.3’ with the intention of requesting a 0.3 unit insulin bolus, the app, unable to register the decimal point, would deliver 3 units of insulin instead of the intended 0.3. This situation could potentially result in an insulin overdose, if the user fails to recognize the error on the calculator screen or the confirmation screen before confirming the dose.

The recall impacts approximately 28,919 Omnipod Systems that were distributed for sale between April 20, 2023 and December 20, 2023.

On December 7, 2023, the manufacturer released a software update to address and correct the issue, and issued a Medical Device Correction notice to all registered customers. The letter requested that customers update the Omnipod 5 Android App to version 1.2.4 and confirm that the displayed insulin bolus amount matches the desired amount.

Customers with further questions about this recall should contact Insulet Customer Care at 1-800-591-3455.

0 Comments

Share Your Comments

This field is hidden when viewing the form
I authorize the above comments be posted on this page*
Post Comment
Weekly Digest Opt-In

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories

Lawyers in Suboxone Dental Lawsuits Fail To Reach Agreement on Bellwether Selection Process
Lawyers in Suboxone Dental Lawsuits Fail To Reach Agreement on Bellwether Selection Process (Posted yesterday)

Plaintiffs involved in Suboxone dental lawsuits indicate the bellwether selection process may be delayed due to the defendants' approach to the discovery process, which they say will cause significant delays in the litigation.